No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
99 |
4. Check minimum number of eventsNone |
99 |
5. Include endpointsNone |
99 |
6. Filter based on genotype QC (FinnGen only) |
99 |
Control definitions (FinnGen only)
- Control exclude
- M13_DORSOPATHY
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Lordosis
based on the number of shared cases.
Similar with more cases:
- Deforming dorsopathies
- Dorsopathies
- Diseases of the musculoskeletal system and connective tissue
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 734 | 405 | 324 |
| Only index persons | 657 | 367 | 290 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 49.32 | 51.11 | 46.88 |
| Only index persons | 48.27 | 50.05 | 46.00 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 99 | 53 | 46 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 47.78 | 47.41 | 48.21 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 90
- Matched controls
- 900
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M40.5
ICD-10 Finland
Lordosis, unspecified
+∞
64.5
54
*
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
321.9
40.4
38
*
L40.5
ICD-10 Finland
Arthropathic psoriasis
+∞
38.3
34
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
20.8
28.3
45
41
M07.3
ICD-10 Finland
Other psoriatic arthropathies
+∞
20.6
19
*
D05AX02
ATC
calcipotriol; topical
27.4
19.1
26
13
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
28.1
18.6
25
12
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
13.9
17.9
32
34
A07EC01
ATC
sulfasalazine; oral, rectal
13.7
17.2
31
33
D05AX52
ATC
calcipotriol, combinations; topical
18.7
16.8
26
19
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
39.4
15.5
19
6
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
177.3
14.9
15
*
D07XC01
ATC
betamethasone, combinations; topical
9.9
14.5
31
45
L40.0
ICD-10 Finland
Psoriasis vulgaris
20.6
14.3
21
13
M40.4
ICD-10 Finland
Other lordosis
+∞
13.9
13
*
7372A
ICD-9 Finland
Curvature of spine, Lordosis (acquired)
+∞
13.9
13
*
M48.0
ICD-10 Finland
Spinal stenosis
163.3
13.8
14
*
L04AA13
ATC
leflunomide; oral
47.8
13.7
16
*
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
34.3
13.5
17
6
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
14.8
12.6
21
18
H02AB06
ATC
prednisolone; systemic
5.1
12.1
61
262
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
13.1
11.5
20
19
D07AC01
ATC
betamethasone; topical
4.8
10.9
49
180
L04AA01
ATC
[U] ciclosporin; systemic
+∞
10.6
10
*
M07.0*L40.5
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
+∞
10.6
10
*
D05AX03
ATC
calcitriol; topical
45.4
10.2
12
*
D07AD01
ATC
clobetasol; topical
5.9
9.9
30
70
E0000UV
ATC
NA
4.2
9.7
53
227
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
21.3
9.2
13
7
E000001
ATC
NA
4.7
9.0
35
107
N03AX16
ATC
pregabalin; oral
5.5
8.9
28
68
N02AX02
ATC
tramadol; systemic, rectal
4.0
8.6
46
187
ABC36
NOMESCO Finland
Decompression of lumbar nerve roots
98.7
8.6
9
*
M073, M405
ICD-10 Finland
NA
+∞
8.5
8
*
M43.1
ICD-10 Finland
Spondylolisthesis
+∞
8.5
8
*
L88
ICPC
Rheumatoid/seropositive arthritis
14.9
8.2
13
10
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
10.3
7.9
15
17
L04AB01
ATC
etanercept; parenteral
49.3
7.9
9
*
N02AA05
ATC
oxycodone; systemic
6.6
7.8
20
37
D05AA
ATC
Tars
86.8
7.5
8
*
S91
ICPC
Psoriasis
+∞
7.4
7
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.5
7.3
22
50
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
8.1
6.5
14
20
M54.5
ICD-10 Finland
Low back pain
3.9
6.5
29
98
E000002
ATC
NA
4.9
6.5
21
52
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
19.7
6.4
9
5
M07.0
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
+∞
6.3
6
*
M43.0
ICD-10 Finland
Spondylolysis
+∞
6.3
6
*
NA3EA
NOMESCO Finland
Lumbar spine X-ray examination with flexion
+∞
6.3
6
*
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
3.6
6.2
32
119
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
60
327
3.12
7.07
6.9
4.4
0.0
0.0
estimate
—
9
60
59
332
2.92
6.34
5.4
3.1
0.0
0.0
estimate
—
6
57
72
456
3.12
6.14
16.2
9.8
3.8
4.0
e9/l
0.73
67
394
57
322
2.82
5.97
5.5
3.2
0.0
0.0
estimate
—
7
57
82
567
3.60
5.87
9.3
3.3
14.1
10.3
mm/h
1.65
77
516
42
233
2.39
4.20
5.7
2.6
—
—
—
0
0
49
301
2.24
3.78
7.8
4.5
1.2
1.2
mmol/l
0.43
43
277
49
302
2.23
3.74
6.4
4.0
34.5
35.6
g/l
0.85
44
284
51
331
2.12
3.31
10.3
5.6
1.2
1.2
mmol/l
0.59
44
286
31
165
2.28
3.30
6.6
3.4
0.0
0.0
estimate
—
9
58
12
39
3.36
3.21
6.3
2.2
1.8
2.7
mmol/l
—
6
31
7
14
5.29
2.78
1.4
1.1
—
—
—
0
0
7
14
5.29
2.78
1.1
1.5
—
—
—
0
0
7
14
5.29
2.78
1.1
1.5
—
—
—
0
0
6
10
6.30
2.74
1.5
1.1
—
—
—
0
0
12
44
2.97
2.65
6.3
2.1
5.6
5.4
kpa
0.09
12
39
41
263
1.95
2.60
6.5
3.2
—
—
—
0
0
15
64
2.58
2.53
2.7
2.1
0.2
0.2
g/l
0.32
15
59
17
78
2.42
2.48
4.3
4.7
213.2
219.4
u/l
0.19
17
73
49
339
1.88
2.44
5.7
3.5
—
—
—
0
0
5
9
5.78
2.24
1.4
1.1
—
—
—
0
0
11
43
2.75
2.18
1.9
1.5
—
—
—
0
0
91
805
2.61
2.09
27.1
11.0
17.6
23.5
mg/l
1.58
77
603
9
32
2.99
2.06
10.2
3.3
25.2
25.5
mmol/l
—
9
32
36
239
1.80
1.96
4.1
3.2
2.3
2.3
mmol/l
0.00
31
212
5
11
4.72
1.96
1.4
1.8
—
—
—
0
0
5
11
4.72
1.96
3.2
1.7
—
—
—
0
0
14
68
2.23
1.80
2.6
1.6
—
—
—
0
0
29
185
1.80
1.78
4.9
2.4
361.6
3658.6
umol/l
0.77
29
164
28
178
1.80
1.74
4.5
1.7
—
—
—
0
0
5
13
3.99
1.73
3.6
1.7
—
—
—
0
0
16
84
2.08
1.71
11.6
3.7
1.1
1.0
mmol/l
0.35
16
76
5
14
3.70
1.63
7.0
1.7
—
—
—
0
0
5
14
3.70
1.63
4.0
1.5
—
—
—
0
0
14
71
2.13
1.63
2.6
1.6
—
—
—
0
0
7
26
2.82
1.61
1.1
1.6
—
—
—
0
0
19
109
1.92
1.61
1.6
1.6
763.0
1176.7
nmol/l
1.39
13
82
9
38
2.50
1.50
2.1
2.5
1.3
1.6
%
—
9
38
38
278
1.60
1.38
1.9
1.6
98.3
95.8
pmol/l
0.11
21
141
37
272
1.58
1.31
5.9
3.2
27.7
77.1
ng/l
1.43
29
180
5
18
2.87
1.30
1.0
1.1
—
—
—
0
0
20
126
1.74
1.27
1.1
1.2
19.7
27.6
iu/ml
—
6
46
17
104
1.77
1.19
3.4
1.8
—
—
—
0
0
5
20
2.58
1.16
1.2
1.3
—
—
—
0
0
18
115
1.69
1.09
1.1
1.2
60.4
3.0
u/ml
—
5
43
5
22
2.34
1.04
1.4
1.6
—
—
—
0
0
5
22
2.34
1.04
1.0
1.1
—
—
—
0
0
5
22
2.34
1.04
1.0
1.1
—
—
—
0
0
6
30
2.06
0.88
3.7
1.6
—
—
—
0
0
5
26
1.97
0.71
3.6
2.4
—
—
—
0
0
5
27
1.90
0.69
3.2
2.2
—
—
—
0
0
65
584
1.33
0.62
3.1
3.6
14.6
14.7
pmol/l
0.14
58
532
5
30
1.70
0.62
1.2
1.1
26.0
39.1
nmol/l
—
5
30
0
21
0.00
0.61
0.0
1.4
—
—
—
0
0
0
21
0.00
0.61
0.0
1.4
—
—
—
0
0
0
21
0.00
0.61
0.0
1.4
—
—
—
0
0
0
23
0.00
0.59
0.0
1.6
—
—
—
0
0
6
36
1.71
0.58
1.5
1.6
—
—
—
0
0
88
833
1.51
0.57
26.3
12.0
139.3
139.8
mmol/l
1.05
88
804
16
119
1.41
0.52
7.9
2.9
0.9
0.8
mmol/l
0.37
16
114
11
76
1.50
0.50
3.5
2.7
—
—
—
0
0
88
838
1.45
0.49
26.5
12.0
4.0
4.0
mmol/l
0.16
88
809
6
42
1.46
0.36
1.0
1.4
—
—
—
0
0
6
42
1.46
0.36
1.3
1.4
—
167.0
iu/ml
—
0
20
6
86
0.68
0.35
22.7
6.0
—
—
—
0
0
58
536
1.20
0.34
3.9
3.1
—
—
—
0
0
11
84
1.35
0.31
6.6
2.3
16.5
7.4
umol/l
0.33
11
72
7
54
1.32
0.31
3.7
3.8
1.2
1.2
mmol/l
—
7
49
91
882
1.39
0.31
28.8
12.8
86.0
76.1
umol/l
0.56
91
882
38
342
1.18
0.29
3.6
2.1
91.4
140.3
ug/l
1.03
38
307
83
798
1.25
0.29
4.3
3.6
1.5
1.3
mmol/l
2.00
77
725
16
132
1.25
0.28
2.0
3.3
2.5
2.5
mmol/l
0.21
11
116
19
219
0.84
0.23
2.6
3.4
22.9
22.3
%
—
7
97
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
13.2
—
0
12
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
22
195
1.16
0.19
2.1
1.6
1.8
1.4
mmol/l
0.64
15
161
83
848
0.87
0.13
4.9
4.5
2.8
2.8
mmol/l
0.15
77
770
81
792
1.13
0.12
20.7
10.6
83.5
84.2
ml/min/173m2
0.09
72
640
10
114
0.86
0.10
1.6
1.4
—
—
—
0
0
25
265
0.92
0.08
3.9
4.1
1.3
3.1
ug/l
0.91
20
236
7
68
1.03
0.08
1.3
1.6
—
—
—
0
0
8
77
1.04
0.07
1.5
1.8
—
—
—
0
0
9
100
0.89
0.06
1.4
1.8
—
—
—
0
0
73
743
0.93
0.06
4.2
4.1
1.8
1.9
mu/l
0.12
68
671
84
830
1.08
0.04
4.7
4.1
4.7
4.7
mmol/l
0.02
78
758
15
152
0.98
0.00
1.3
1.5
—
—
—
0
0
83
826
1.03
0.00
4.7
4.0
1.4
1.5
mmol/l
1.13
77
749
76
759
1.01
0.00
6.0
5.3
39.3
39.6
mmol/mol
0.10
71
704
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
7
72
0.97
0.00
3.3
1.8
8.9
15.0
nmol/l
—
7
66
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1612.4
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_LORDOSIS and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_LORDOSIS | 1.788 [1.23, 2.6] | 0.002 |
| Birth year | 0.984 [0.97, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 68 out of 251 males with M13_LORDOSIS died.
Mortality risk
Mortality risk for people of age
years, who have M13_LORDOSIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 0.306% |
| 5 | No data | 1.995% |
| 10 | No data | 5.138% |
| 15 | No data | 9.005% |
| 20 | No data | 15.167% |
Relationships between endpoints
↥Index endpoint: M13_LORDOSIS – Lordosis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data